Immuneering Corporation Class A Common Stock Earnings Recaps
Q3 2025
Nov 13, 2025
Immuneering Corporation delivered a compelling third quarter of 2025 highlighted by promising clinical results from its Phase 2a trial of atebimetinib in combination with FOLFIRINOX for pancreatic cancer patients.
Key takeaways
- Reported significant overall survival improvements in first-line pancreatic cancer patients treated with atebimetinib and FOLFIRINOX, strengthening development pipeline.
- A case study showcased a 71-year-old patient achieving a 100% reduction in liver lesions after five months of treatment, indicating strong efficacy and safety profile.
- Company plans to share substantial data updates in 2026, with potential presence at major medical meetings.
- Ongoing trials aim to enhance treatment options for pancreatic cancer, which remains a significant area of unmet medical need.